Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer
LabRoots Drug Discovery 2018 Virtual Event
|SPEAKER:||Michael A. Davies, M.D., Ph.D, Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center|
Feb 22, 2018
The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies. There is now strong evidence of cross-talk between oncogenic signaling pathways in tumors and the anti-tumor immune response, supporting the need for concurrent evaluation of immune and molecular phenotypes in patient samples. Further, there is growing evidence of the heterogeneity of immune and molecular phenotypes between, and even within, tumors. This webinar will explore oncogenic signaling pathways, resulting immune responses and the impact of heterogeneity in cancer. Examples of studies will be presented in which Digital Spatial Profiling has been used to assess immune and molecular features to make insights into the pathogenesis of melanoma.